NAGE
Niagen Bioscience Inc
NAGE's fundamentals are weak: its operating margin fell 12 points to 3.9% and free cash flow fell 77%. At 18x earnings, it's trading below its usual 28x. Analysts expect earnings to fall sharply, though they disagree widely on how much.
NAGE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Strong |
NAGE's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
NAGE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $2.05 | -3.7% |
| Current | 18x | $2.13 | — |
| Fair | 27x | $3.30 | +55% |
| Expensive | 79x | $9.47 | +345% |
| Forward | 217x | $2.13 | — |
Historical ranges are pointers, not guarantees.
NAGE's PE is in its cheap range at 18x. Analysts expect earnings to fall, which would put today's price at 217x next year's earnings, in its expensive range.
NAGE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NAGE's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
NAGE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | -92% |
| Q3 2026 | $0.12 | -52% |
| Q2 2026 | $0.18 | -18% |
| Q1 2026 | $0.21 | +17% |
| Q4 2025 | $0.20 | +82% |
| Q3 2025 | $0.25 | +2400% |
| Q2 2025 | $0.22 | +$0.24 |
| Q1 2025 | $0.18 | +$0.23 |
| Q4 2024 | $0.11 | +$0.18 |
NAGE's earnings per share have fallen from their peak: $0.12 over the past year, against $0.25 in late 2025.
NAGE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.2M | -20% |
| Q2 2026 | $29.8M | -4.3% |
| Q1 2026 | $31.5M | +3.3% |
| Q4 2025 | $33.8M | +16% |
| Q3 2025 | $34M | +33% |
| Q2 2025 | $31.1M | +37% |
| Q1 2025 | $30.5M | +38% |
| Q4 2024 | $29.1M | +37% |
NAGE's revenue fell from its 2025 peak and has held roughly level since: $27M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.8% | -18 points |
| Q2 2026 | 2.4% | -7.9 points |
| Q1 2026 | 5% | -11 points |
| Q4 2025 | 12% | -12 points |
| Q3 2025 | 12% | +6.2 points |
| Q2 2025 | 10% | +11 points |
| Q1 2025 | 16% | +19 points |
| Q4 2024 | 24% | +25 points |
NAGE's operating margin was −5.8% last quarter, down 18 points from the same quarter a year ago.
NAGE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6M | -29% |
| Q2 2026 | $2.8M | +122% |
| Q1 2026 | -$1.2M | -115% |
| Q4 2025 | $679K | -92% |
| Q3 2025 | $3.7M | +5.6% |
| Q2 2025 | $1.3M | +$1.5M |
| Q1 2025 | $7.9M | +2572% |
| Q4 2024 | $8.6M | +1222% |
NAGE still generates free cash flow, though less than at its 2024 peak: $5M over the past year.
NAGE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -3.4M shares |
| 1 year | -8.6% | -7.5M shares |
| 3 years | +5.5% | +4.1M shares |
| 5 years | +16% | +10.9M shares |
| Available history | +28% | +17.5M shares |
NAGE has 79M diluted shares, down 8.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $2.8M |
| Q1 2026 | $2.4M |
NAGE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -11.9x | Net Cash |
| Q2 2026 | -5.8x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -3.8x | Net Cash |
| Q3 2025 | -3.2x | Net Cash |
| Q2 2025 | -3.5x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -5.2x | Net Cash |
NAGE has more cash than debt.
NAGE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 3.5 | Oversold |
NAGE's weekly RSI is 23 (oversold) and its Stochastic is 4 (oversold).
NAGE PE vs Healthcare Sector
| Metric | NAGE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 22 | 29 | 7 pts below |
NAGE is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
NAGE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.50 | 15% below |
| 20 week MA | $2.93 | 27% below |
| 50 week MA | $4.14 | 49% below |
| 100 week MA | $6.23 | 66% below |
| 200 week MA | $4.35 | 51% below |
NAGE is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
NAGE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.47 | $4.99 | +12% |
| 2021 | $4.99 | $4.13 | -17% |
| 2022 | $4.13 | $1.50 | -64% |
| 2023 | $1.50 | $1.43 | -4.7% |
| 2024 | $1.43 | $5.52 | +286% |
| 2025 | $5.52 | $6.64 | +20% |
| 2026 YTD | $6.64 | $2.13 | -68% |
NAGE's yearly returns have swung widely, from +286% in 2024 to −64% in 2022. It's down 68% so far in 2026.